METHODS AND CONSTRUCTS FOR PROTEIN EXPRESSION

Abstract: The invention teaches methods, constructs and host cells for the effective expression of a desired protein in mammalian cell culture. In particular, the efficient expression of human GGF2 is taught.

Description: METHODS AND CONSTRUCTS FOR PROTEIN EXPRESSION Field of the Invention The invention relates to the field of gene expression technology and the production of protein using transformed host cells and recombinant DNA vectors. In particular, the invention relates to the area of efficient protein production in transformed mammalian host cells, and methods, constructs and host cells for effecting such. Background of Invention Efficient means of expressing cloned genes as protein product are an essential tool for the identification and characterization of cloned genes, the generation of large quantities of protein for structure-function analysis, and the production of protein for use in medicinal pharmaceutical preparations. Protein expression systems are described in the literature, and for example as found in such reference works as Gene Expression Technology. Methods in Enzymology Vol. 185 (ed. David Goeddel et al., Academic Press, Inc., London, 1991), Gene Structure and Expression. 2 nd Edition. J.D. Hawkins (Cambridge University Press, London, 1991) and their cited references. The expression of simple proteins can be routinely accomplished by using suitable Escherichia coli expression systems, however, these systems are typically inadequate for the expression of complex mammalian proteins. Mammalian expression systems have been developed for use in protein expression systems, however these systems have complex culture media requirements, and are extremely difficult and costly to maintain as large-scale, long-term culture systems. Adaptation of protein producing cell lines to low-protein or serum- free media has been one method of simplifying the final purification of desired protein product, as described for example in U.S. Patent 4,757,005 (incorporated by reference in its entirety). Many improved nutrient medium and serum free medium have been described in U.S. Patents 5,143,842; 4,560,655; 5,024,947; 4,533,637; 4,767,704; 4,816,401 ; 5,631,159; 5,135,866 (these and all subsequently identified patents are hereby incorporated by reference in their entirety) and the literature, as in for example Hedlund and Miller "A Serum-Free Defined Medium Capable of supporting growth of four established human prostatic carcinoma cell lines" The Prostate 24:221- 228 (1994). Methods for the culture of mammalian cells have also been described, as in U.S. Patent 5,122,469 and the literature. Large-scale culture and protein production techniques and apparatus have also been described, as in U.S. Patents 5,081,035 and 5,153,131, and the literature. Thus it is well recognized in the art that there is a need for mammalian protein expression systems and methods, and in particular protein- free mammalian protein production systems suitable for large-scale protein production. This is especially true given the recent discovery of and fear of prion transmission and related disease from the use of mammalian protein supplements, especially sheep and bovine protein products. The present invention addresses this need and describes the unexpected discovery that mammalian host cells can be adapted for efficient protein expression of a desired protein, by the transformation or co-transformation of the host cell for the expression of an additional protein, said additional protein being either alpha-2-HS-glycoprotein, or a mammalian fetuin protein. For simplicity, in the remainder of the specification, unless otherwise identified, the term "fetuin" shall mean human alpha-2-HS-glycoprotein (AHSG), and all mammalian fetuin protein equivalents, including and not limited to bovine, murine, porcine, equine, and rat, their orthologs and derivatives. Fetuin was the first fetal protein characterized in fetal calf serum, and was found to be homologous to human alpha-2-HS-glycoprotein (Dziegielewska et al, 1993, "alpha-2-HS- glycoprotein is expressed at high concentration in human fetal plasma and cerebrospinal fluid", Fetal Diagn. Ther. 8:22-27). The alpha-2-HS-glycoprotein is predominantly produced by liver hepatocytes, and is thought to undergo post-translational modification (Jahnen-Dechent et al., 1994, "Posttranslational processing of human alpha-2-HS-glycoprotein (human fetuin)" Eur. J. Biochem. 226:59-69). The cystatin-like domain of murine countertrypin has been found to inhibit trypsin (Yoshida et al., 1996, "Cystatin-like domain of mouse countertrypsin, a member of mammalian fetuin family, is responsible for the inhibition of trypsin" Biochemistry and Molecular Biology International 39(5): 1023- 1028). Fetuin/ alpha-2-HS-glycoprotein has been found to be expressed during embryogenesis and found to promote bone remodeling and stimulate cell proliferation, as well as to act as an antagonist to the antiproliferative action of transforming growth factor betal (TGF-βl) (Demetriou et al, 1996, "Fetuin/ alpha-2-HS- glycoprotein is a transforming growth factor- β Type II receptor mimic and cytokine antagonist", J. Bio. Chem. 271(22): 12755-12761). Rat phosphofetuin (phosphorylated fetuin) was found to modulate hepatocyte HGF activity (Ohnishi et al., 1997, "Effect of phosphorylated rat fetuin on the growth of hepatocytes in primary culture in the presence of human hepatocyte-growth factor". Eur. J. Biochem. 243:753-761). Fetuin, as a component of fetal calf serum, has been identified as a component of basic culture media, as in for example, U.S. Patent 4,757,005, and 5,143,842. However, it is the present invention which discovered that the transformation of host cells to express fetuin in conjunction with expression of a desired protein product allows for the efficient expression of the desired protein, and for the simplified transition of the transformed host cells to a serum- free or reduced protein culture system, allowing for large-scale production of protein. Brief Description of the Invention The present invention encompasses the fundamental discovery that efficient expression of a desired protein can be accomplished by using a mammalian host cell that is also expressing fetuin protein. Such a transformed host cell expressing fetuin and a desired protein is thus suitable for adaptation to serum-free, or low protein large-scale culture protein production. The fetuin of the present invention encompasses human alpha-2-HS-glycoprotein (AHSG), and all mammalian fetuin protein equivalents, including and not limited to bovine, murine, porcine, equine, and rat, their orthologs and derivatives. In a preferred embodiment of the invention, the fetuin is either human or bovine, their orthologs and derivatives. The instant invention encompasses efficient expression of a desired protein in all mammalian cell culture systems, including and not limited to large-scale, serum-free, hollow- fiber, suspension culture, adherent culture, fermentation culture, and small-scale protein expression. In particular, the instant invention is directed to low-protein or serum-free expression systems. The mammalian host cells suitable for use in the present invention include, and are not limited to CHO cells, HeLa cells, and other mammalian cells adapted for expression of recombinant proteins. The mammalian host cells of the present invention can be cells which normally express fetuin, and so are selected for such expression, selected for higher expression, or adapted for such expression. Such pre-existing fetuin expression cells can be modified to express higher levels of fetuin than normally produced, via genetic manipulation of the endogenous genome or transfection with one or more suitable expression vector(s). The mammalian host cells of the present invention can be normally non-expressing for fetuin, and following the teaching of the present invention, transformed to express fetuin. The transformation of suitable host cells for the expression of fetuin can be accomplished by either transformation with a suitable expression vector containing an exogenous fetuin gene, or by adaptation of the host cell to express endogenous fetuin gene. The desired protein product can be expressed from the fetuin adapted host cell by means of standard expression vectors, or by the manipulation of the host cell genome to integrate and express desired protein. It is also possible to construct an expression vector which expresses both fetuin and the desired protein. In such a case, the fetuin gene and the gene for the desired protein can be under the control of either the same or different promoter/enhancer systems. It is not beyond the scope of the present invention to produce fetuin-desired protein fusion products for expression. One particular embodiment of the present invention encompasses an improved mammalian expression vector for recombinant human glial growth factor 2 (GGF2), the GGF2 cell lines CHO (dhfr 7GGF2) transformed with such a vector, CHO(dhfr /α2HSGP/GGF2) that are capable of stable and augmented secretion levels of GGF2, and a protein-free production process for GGF2 by continuously perfusing the cells of the invention in a fermenter. Thus the present invention encompasses a method for producing a desired protein from a recombinant DNA expression vector in a mammalian host cell, said method comprising transforming a mammalian host cell with an expression vector containing an expressible mammalian fetuin gene, transforming the same mammalian host cell with an expression vector containing an expressible gene which encodes for a desired protein, expanding said transformed host cells in culture, and isolating said desired protein from said culture. The present invention further contemplates the method wherein said vector containing an expressible mammalian fetuin gene, or said expression vector containing an expressible gene which encodes for a desired protein also contains a gene encoding for a selectable marker. It is also contemplated that said expression vector containing an expressible mammalian fetuin gene also contains an expressible gene which encodes for a desired protein. The present invention encompasses an expression vector comprising, a promoter, a coding sequence for fetuin, said coding sequence being operably linked to the promoter, an intronic sequence, the intronic sequence being downstream of the promoter and upstream of the fetuin coding sequence, the intronic sequence comprising two identical donor sites and one acceptor site, and a coding sequence of a heterologous protein, the coding sequence being operably linked to a promoter. It is contemplated that the order of transformation of a target host cell, when using two expression vectors, can be such that said mammalian host cell is first transformed with an expression vector containing an expressible mammalian fetuin gene. It is thus contemplated by the methods of the present invention that a target host cell is first transformed with an expression vector containing an expressible gene which encodes for a desired protein. Thus the invention encompasses a method for producing a transformed mammalian host cell for production of a desired protein from a recombinant DN A expression vector in said mammalian host cell, said method comprising transforming a mammalian host cell with an expression vector containing an expressible mammalian fetuin gene, and transforming the same mammalian host cell with an expression vector containing an expressible gene which encodes for a desired protein. Also contemplated is such a method wherein said vector containing an expressible mammalian fetuin gene, or said expression vector containing an expressible gene which encodes for a desired protein also contains a gene encoding for a selectable marker. In one further embodiment of the invention, the method for producing a host cell of the invention is contemplated wherein said expression vector containing an expressible mammalian fetuin gene also contains an expressible gene which encodes for a desired protein, and wherein said expression vector contains a gene which encodes for a selectable marker. The method of the invention for producing transformed host cells contemplates a method where said mammalian host cell is first transformed with an expression vector containing an expressible mammalian fetuin gene, or a method where said mammalian host cell is first transformed with an expression vector containing an expressible gene which encodes for a desired protein. A further embodiment of the invention are host cells produced by the methods of the invention. In particular, the invention encompasses a mammalian host cell for the expression of a desired protein in cell culture, wherein said host cell is transformed with an expression vector containing an expressible mammalian fetuin gene, and a second expression vector containing an expressible gene encoding for a desired protein. Also contemplated, and encompassed by the instant invention is a mammalian host cell for the expression of a desired protein in cell culture, wherein said host cell is transformed with an expression vector containing an expressible mammalian fetuin gene, and an expressible gene encoding for a desired protein. The methods of the present invention also encompass the production of a desired protein from a cell culture wherein the cells of said cell culture are transformed with an expression vector containing an expressible fetuin gene, and wherein said cells also express a desired protein. Such methods also encompass the production of a desired protein from host cells which have been selected or otherwise manipulated for enhanced fetuin expression, and are expressing a desired protein. In order to aid efficient transformation of host cells, it is contemplated that the methods of the invention include the use of a expression vector which also contains a gene which encodes for a selectable marker. In a particular aspect, the invention encompasses the methods and host cells described above, wherein said expression vector containing a fetuin gene is the expression vector pSV- AHSG. One particular embodiment of the present invention are methods and host cells as described above wherein said expression vector containing a gene encoding for a desired protein is pCMGGF2, and said desired protein is human Glial Growth Factor 2 (GGF2). In on particular embodiment, the invention encompasses the fetuin adapted host cell CHO-α2HSGP and progeny or derivatives thereof. Thus, in a particular aspect, the invention specifically encompasses the nucleic acid sequence of the expression vector pSV-AHSG, and of expression vector pCMGGF2. Brief Description of the Figures The embodiments and constructs of the invention can be better understood with reference to the following figures in which: Figure 1 is a diagram illustrating an expression vector for human alpha-2-HS-glycoprotein (expressing SEQ ID NO.: 5 encoding for a human fetuin ortholog protein SEQ ID NO.: 6), pSV- AHSG. Figure 2 is a diagram illustrating an improved GGF2 expression vector pCMGGF2. Figure 3 is a chart which illustrates efficient protein- free production of GGF2 using a continuously perfused fermenter and CHO host cells transformed with the vector pCMGGF2. Figure 4A shows a linear map of the CMV promoter, a 5 '-intronic sequence (MIS), and Hpal cloning site. The parallel map shows the location of the 177 bp intron within the MIS sequence. Figure 4B shows the nucleotide sequence of MIS (SEQ ID NO.: 1 1). Denoted are the nucleotide sequence derived from EBV (bracketed) and its two donor-site (Open parenthesis signal) and one acceptor-site (close parenthesis signal). Two repeated sequences (2 x 71 bp) are underlined (thin and thick). Detailed Description of the Invention The present invention encompasses the unexpected discovery that mammalian host cells can be adapted for efficient protein expression of a first desired protein, by the transformation of the host cell for the production of a first protein, wherein said first protein is either alpha-2-HS- glycoprotein, or mammalian fetuin. The methods, constructs and host cells of the invention are suitable for production of desired protein in standard small-scale culture systems, as well as large-scale production systems, including and not limited to fermenter systems, hollow fiber culture systems, tumbler systems, and suspension culture systems. Protocols and methods for the manipulation of nucleic acids, PCR amplification of nucleic acids, construction of expression vectors, transformation of host cells, and the culture of transformed cells for the production of protein are known in the art and can be found in a variety of laboratory manuals or texts, see generally Sambrook et al., 1989 Molecular Cloning. 2 nd edition, Cold Spring Harbor Press; Ausubel et al, 1992 Short Protocols in Molceular Biology. 2 nd edition, John Wiley & Son; Gene Expression Technology. Methods in Enzymology Vol. 185 (ed. David Goeddel et al, Academic Press, Inc., London, 1991); Gene Structure and Expression. 2 nd Edition, J.D. Hawkins (Cambridge University Press, London, 1991); PCR Protocols: A Guide to Methods and Applications (Innis, et al. 1990, Academic Press, San Diego, CA); Culture of Animal Cells: A Manual of Basic Technique. 2nd Ed. (R.I. Freshney. 1987, Liss, Inc. New York, NY); Methods in Molecular Biology (Vol. 7), Gene Transfer and Expression Protocols, (ed. E.J. Murray, 1991, The Humana Press Inc., Clifton, N.J.); Ramsay, M., Yeast Artificial Cloning, 1994, Molec. Biotech. 1 : 181-201; and, Smith, et al. 1990. Amplification of large artificial chromosomes Proc. Natl. Acad. Sci. USA 87: 8242-8246. The invention and many of its aspects can be better understood by way of illustration in the following examples. Example 1 : Fetuin Expression and Host Cells Using an expression vector suitable for transfection of mammalian cells, a nucleic acid sequence encoding for a human fetuin gene ortholog of SEQ ID. NO: 5 was operably inserted and the complete vector transformed into CHO host cells. One example of a fetuin expression vector of the present invention is pSV-AHSG (Fig. 1). A suitable starting expression vector is one which would be suitable for accepting the insertion of a desired fetuin gene, such that it is operably linked to a suitable promoter/enhancer system. AHSG was cloned by reverse transcriptase-mediated PCR (RT-PCR) techniques using human liver mRNA (Clonetech, Palo Alto, CA). The sequence for the PCR primers were 1 ) 5 '-CCT CCA ACC ACC TGC ACG CC (SEQ ID NO.: 7) and 2) 5'-GTG GCT ATG TTT TCT GTG CC (SEQ ID NO.: 8). In order to allow for efficient selection and maintenance of stable transformation, the preferred suitable expression vector can contain one or more selectable marker gene, for example an antibiotic resistance gene, or otherwise required metabolic protein when paired with a suitably deficient host cell. In contemplated embodiments of the present invention, a suitable expression vector can contain a nucleic acid encoding any suitable mammalian fetuin, for example bovine fetuin, murine fetuin, porcine fetuin, equine fetuin or rat fetuin. The nucleic acid sequences encoding for mammalian fetuin genes are known in the art and are available in the GenBank data bank, including Human (#36317), Rat BSP (#89822), Rat ρp63 (#92482), Rat fetuin (#94301), Bovine fetuin (#101386), Ovis aries fetuin (#104788), and S. scrofa fetuin (#108394). Prefered fetuin genes are Human (#36317) (SEQ ID No. 3), and Bovine fetuin (#101386) (SEQ ID No. 1), their homologs and orthologs, such as for example the nucleic acid sequence of SEQ ID No. 5. Suitable mammalian host cells are then transformed with a fetuin expression vector and selected for stable transfection. In a preferred embodiment, the starting host cells are CHO cells, and after transfection have the phenotype (dhfr7α2HSGP). Suitable host cell lines in which constitutive expression of fetuin occurs allows for enhanced protein expression from an expression vector. Constitutive expression of fetuin can be established by sequential transfection of host cells with an expression vector containing a fetuin gene; screening and selection for transformed cells expressing fetuin protein; then subsequent transfection of the selected cells (or progeny thereof) with an expression vector containing a gene or genes of the desired protein or proteins to be expressed. A preferred method involves co-transfection of host cells with separate expression vectors, wherein one vector would encode for a fetuin gene, and the other vector or vectors would encode for one or more desired proteins. However, one of ordinary skill in the art would know how to construct combined expression vectors wherein a fetuin gene is expressed from the same vector as that encoding for and expressing one or more desired proteins. A further permutation of the invention would involve co-transfecting such a combined fetuin/protein expression vector with one or more additional expression vectors which encode for desired protein(s). As one of ordinary skill in the are would recognize, several permutations of the present invention can be constructed and used without undue experimentation. Once the transformed host cells are established, it is possible to further screen and select such transformed host cells for additional phenotypic properties such as protein expression level, growth rate, and growth conditions such as temperature, media requirements and suitability for growth in low-protein or serum-free media. In particular, CHO cells can be transformed with plasmid pSV-AHSG to result in the fetuin adapted host cell called CHO-α2HSGP (CHO phenotype dhfr7α2HSGP). Example 2 : Recombinant human glial growth factor (GGF2) Although the etiology of multiple sclerosis (MS) remains unknown, treatment strategies for this demyelinating disease have been based on the modulation of the immunological events that accompany the formation of MS lesions (Waubant EL, Oksenberg JR, and Goodkin DE. 1997. Pathophysiology of multiple sclerosis lesions. Science & Medicine 4: 32 - 41). Beta- interferon is one of the immunomodulators that has been used successfully to treat relapsing forms of MS. Other factors such as mitogenic growth factors for oligodendrocytes have been identified as one of the emerging treatment strategies for MS. The therapeutic potential of these neurotrophic factors was surmised to promote remyelination. Recombinant human glial growth factor (GGF2) is one of these factors with documented stimulatory effects on Schwann cells and oligodendrocytes (Mahanthappa NK, Anton ES, and Matthew WD. 1996. Glial growth factor 2, a soluble neuregulin, directly increases Schwann cell motility and indirectly promotes neurite outgrowth. J. Neuroscience 16: 4673 - 4683). A method for the production of GGF2 for treatment of neurodegenerative disorders and demyelination in peripheral or central nervous system has been described in US Patent 5,530,109 (incorporated by reference in its entirety). Using both the expression vector and production cell lines that were described in US Patent 5,530,109 their productivity was evaluated. To our surprise these cell lines have rather low specific productivity (0.5 - 1 pg/c/d) and are unstable. Subsequently we tried to derive high producing cell lines using this vector without success. The transfection efficiency was so low that selection in methotrexate yielded only one transformant out of 14 million cells. In order to derive stable cell lines with high productivity for GGF2, an improved vector was constructed. Derivation of production cell lines was done in Chinese hamster ovary cells, CHO (dhfr ) and CHO (dhfr7α2HSGP) cells using the improved vectors. Selection of high producing cells was done in various concentrations of methotrexate. Protein-free clones were derived by gradual weaning of cells from serum proteins. The specific productivity of these clones is in the range of 20-30 pg/c/d. Protein- free conditions can be defined as the absence of substantially all human and animal serum and plasma derived proteins in the culture media, where said proteins may be present in trace amounts, but still supplemented with human insulin. It is preferred that the supplemental insulin be recombinant human insulin. Example 3. Construction of GGF2 expression vectors For efficient transcription, the EBV BMLF-1 intervening sequence (MIS, a 5'- intronic sequence; 5 '-IS) was inserted immediately upstream of the GGF2 cDNA, and downstream of the promoter. Specific methods and examples of for the generation of vectors such as pSM97 is described in U.S. Patent XXXXXXX, (recently allowed application no. 08/807,415 filed February 28, 1997 wherein when the Patent number is known it will be substituted for the application data). The MIS sequence was generated by polymerase chain reaction (PCR) amplification from Epstein-Barr virus (EBV) reading frame designated BMLF1. This MIS sequence encompasses DNA sequence from 84,105 to 84,262 of B95-8 Epstein-Barr virus including an intronic sequence from 84,122 to 84,227 of B95-8 EBV (Farrell, Advances in Viral Oncology, Vol. 8, ed. G. Klein, Raven Press, Ltd., New York, 1989; Genbank access #X00784). Two PCR primers 1) 5'-GGATCGATAACTAGCAGCATTTCCT-3' (SEQ ID NO.: 9) and 2) 5'-GGGTTAACTTCCAGAATGTGGCTCT-3' (SEQ ID NO.: 10) have extended restriction enzyme sites for Clal (ATCGAT) and Hpal (GTTAAC) at the 5' and 3' ends respectively, for amplification and subsequent directional cloning of the MIS fragment. Of course other suitable restriction sites can be designed. Using as a starting construct, expression vector pCIS-F8, having a stabilizing sequence (termed CIS) downstream of a promoter and upstream of the DNA encoding factor VIII (EP 0260148, published Sep. 17, 1987, incorporated by reference), the PCR MIS fragment, described above, digested with Hpal and Clal was inserted into the Clal/Hpal site of pCIS-F8 (after removal of the Factor VIII gene sequence). The resulting plasmid containing MIS was named pSM95. This MIS sequence (5 '-IS) differs from the original EBV sequence by having an unexpected repeat of a 71 bp sequence which contains a donor site. This new MIS sequence (5 '-IS, 229 bp) has two donor-sites and one acceptor-site. (See Figure 4). The intronic sequence CIS was removed from pSM95 by SacII/Clal digestion. The remaining backbone was blunt ended by Klenow and religated. This resulting plasmid, pSM97, consists of a CMV promoter/enhancer (CMVe/p), MIS, a unique Hpal site for cloning, a poly A signal, and a SV40 early promoter-dhfr in a plasmid backbone containing ori and amp r gene. Digestion of the plasmid pCGIG-HBS5 (US Patent 5,530,109) with EcoRI released the recombinant human GGF2 cDNA which was blunt-end ligated to the vector pSM97 at the unique Hpal site. The resulting construct is called pCMGGF2 (Fig. 2). Example 4. Derivation of GGF2 cell clones Transfections. CHO (dhfr " ) and CHO (dhfr7α2HSGP) cells were transfected with plasmid DNA using the cationic lipid DMRIE-C reagent (Life Technologies # 10459-014). Triplicate wells of a 6-well plate were used for each plasmid DNA transferred into CHO (dhfr ) or CHO (dhfr /α2HSGP) . Briefly, in each well of a 6-well plate, 10 μl of DMRIE-C reagent was mixed with 2-5 μg of pCMGGF2 DNA in 0.5 ml of serum-free DMEM-F12 medium. The plate was incubated at room temperature for 30 minutes to allow formation of the lipid-DNA complexes. Subconfluent cells from one T-75 cm 2 flask were trypsinized with 0.5 ml IX Trypsin-EDTA diluted in PBS (GibcoBRL # 15400-054), stopped with 5 ml of growth medium, washed once with PBS, and resuspended in serum free DMEM-F12 medium to 10 7 cells/ml. Then 2xl0 6 logarithmically growing cells in 0.2 ml of serum-free medium was added to each well, followed by incubation of the plate for 4-5 hours at 37°C in a C0 2 incubator. To each well, 2 ml of growth medium with 5% define FBS was added. The cells were assayed by ELISA at 48 to 72-hour post-transfection for transient expression. Drug selection and gene amplification Two to three days post transfection, cells from triplicate wells per transfection were trypsinized, pooled, and washed once with serum free medium. Viable cell densities were determined by the Trypan Blue exclusion method, then seeded in 96-well plates in 5% dialyzed FBS, 50 nM methothrexate selection medium. After screening for GGF2 secreting populations by ELISA, direct selection and amplification steps were carried out in increasing concentrations of methotrexate (100 nM, 200nM, 400 nM, 1 μM ) at 4-6 weeks intervals in a 6-well format with 3 ml of selection medium per well. Limiting dilution cloning (LDC) Single cell clones (SCC) were obtained by LDC at one cell in 200 μl medium per well of a 96-well format, in drug-free selection medium containing 1% dialyzed FBS. The cultures were fed once a week. After two weeks, the plates were scored for single cell growth by phase microscopy prior to ELISA screening. Other suitable methods and constructs for selecting transfected cell lines for heterologous protein expression are described in the literature, and for example in U.S. Patent 5,612,213. GGF2 ELISA A sandwich immunoassay for the detection of rhGGF2 in tissue culture supernatants was performed using standard procedures, (see generally Sambrook et al, 1989 Molecular Cloning. 2 nd edition, Cold Spring Harbor Press; Ausubel et al., 1992 Short Protocols in Molceular Biology. 2 nd edition, John Wiley & Son; Rose et al., 1986 Manual of Clinical Laboratory Immunology. 3 rd edition, American Society of Microbiologists for suitable immunoassay protocols and methods.) On the addition of substrate, the amount of antibody antigen- peroxidase conjugated antibody complex can be measured by spectrophotometry. Samples can be compared against a standard curve of absorbance versus rhGGF2 concentration. Example 5. Protein-free adaptation and evaluation of cell clones The selected GGF2 clones were weaned from 1% FBS by a stepwise twofold dilution in shake flask. Clone F10-B3, the highest producer with specific productivity of 20 pg/c/d, was protein- free adapted in a 1.5-liter fermenter using the basal production medium. The basal protein-free production medium is an enriched DMEM-F12 medium, supplemented with 2 raM Glutamine, 100 μM CaCl 2 , 250 μM L-Histidine, 50 μM FeSO 4 /EDTA, 2 g/L NaHCO 3 10 μg/ml recombinant human insulin, and 0.1% Pluronic F68 (Table 1). The medium maintains a pH range of 7.0-7.3 and an osmolarity range of 280-300. Table 1 Transfection Efficiency of GGF2 Expression Vectors Example 6. Production of GGF2 A continuous protein-free production method for GGF2 was developed by seeding a 1.5-liter fermenter with clone F10-B3 cells using the basal production medium described above. The cell density of the fermenter was maintained at -2 x 10 6 cells/ml and perfused at a rate of 0.5 liter/day. As shown in Figure 3, the cells continued to produce high levels of GGF2 throughout the 34-day production period. Titer as high as 240 mg/liter/day was observed. This continuous perfusion method can be easily adapted to large fermenters (200 to 500-liter) equipped with cell retention devices such as settlers. For example, using a 10-L fermenter, > 40 g of GGF2 can be produced over a 60-day period using the methods and constructs of the present invention. The prior art vector pCDIG-HBS5 described in US Patent 5,530,109 has very low transfection efficiencies. CHO (GGF2) clones generated by this vector not only have low specific productivity (0.5-1.0 pg/c/d) in serum free conditions but are also unstable. Surprisingly, the improved plasmid of the invention, pCMGGF2 supports stable and high expression of GGF2, and efficient selection and amplification of the dhfr gene under methotrexate selection and amplification. Clones derived with the improved vector display stable GGF2 expression and high specific productivity (20-30 pg/c/d) under protein- free conditions. Productivity of various cell lines was further compared. Table 2 below compares the productivity of CHO and CHO-α2HSGP cells expressing GGF2 under serum- free conditions. Surprisingly the specific productivity of serum free clones adapted for fetuin expression were increased 2 - 8 fold higher than regular CHO cells. Table 2 Enhanced Production of GGF2 in CHO Cells - Constitutive Expression of Fetuin With certain embodiments of the invention being fully described, one of ordinary skill in the art will understand and be able to construct various equivalents of the present invention without departing from the spirit or scope of the present disclosure, in view of the claims below.

Claims: We Claim: 1. A method for isolating a desired protein from a mammalian host cell, said method comprising transforming a mammalian host cell with an expression vector containing an expressible mammalian fetuin gene, transforming the same mammalian host cell with an expression vector containing an expressible gene which encodes for said desired protein, expanding said transformed host cells in culture, and isolating said desired protein from said culture. 2. A method of claim 1 wherein said vector containing an expressible mammalian fetuin gene, or said expression vector containing an expressible gene which encodes for a desired protein also contains a gene encoding for a selectable marker. 3. A method of claim 1 wherein said expression vector containing an expressible mammalian fetuin gene also contains an expressible gene which encodes for a desired protein. 4. A method of claim 3 wherein said expression vector contains a gene which encodes for a selectable marker. 5. A method of claim 1 where said mammalian host cell is first transformed with an expression vector containing an expressible mammalian fetuin gene. 6. A method of claim 1 where said mammalian host cell is first transformed with an expression vector containing an expressible gene which encodes for a desired protein. 7. A method for producing a transformed mammalian host cell for production of a desired protein from a recombinant DNA expression vector in said mammalian host cell, said method comprising transforming a mammalian host cell with an expression vector containing an expressible mammalian fetuin gene, and transforming the same mammalian host cell with an expression vector containing an expressible gene which encodes for a desired protein. 8. A method of claim 7 wherein said vector containing an expressible mammalian fetuin gene, or said expression vector containing an expressible gene which encodes for a desired protein also contains a gene encoding for a selectable marker. 9. A method of claim 7 wherein said expression vector containing an expressible mammalian fetuin gene also contains an expressible gene which encodes for a desired protein. 10. A method of claim 9 wherein said expression vector contains a gene which encodes for a selectable marker. 11. A method of claim 7 where said mammalian host cell is first transformed with an expression vector containing an expressible mammalian fetuin gene. 12. A method of claim 7 where said mammalian host cell is first transformed with an expression vector containing an expressible gene which encodes for a desired protein. 13. A mammalian host cell for the expression of a desired protein in cell culture, wherein said host cell is transformed with an expression vector containing an expressible mammalian fetuin gene, and a second expression vector containing an expressible gene encoding for a desired protein. 14. A mammalian host cell for the expression of a desired protein in cell culture, wherein said host cell is transformed with an expression vector containing an expressible mammalian fetuin gene, and an expressible gene encoding for a desired protein. 15. A method of claim 2 wherein said expression vector containing a fetuin gene is the expression vector pSV-AHSG. 16. A method of claim 3 wherein said expression vector containing a gene encoding for a desired protein is pCMGGF2. 17. A mammalian host cell of claim 13, wherein said expression vector containing a fetuin gene is the expression vector pSV-AHSG. 18. A mammalian host cell of claim 13 wherein said expression vector containing a gene encoding for a desired protein is pCMGGF2. 19. An expression vector comprising: a) a promoter b) a coding sequence for fetuin, said coding sequence being operably linked to the promoter, c) an intronic sequence, the intronic sequence being downstream of the promoter and upstream of the fetuin coding sequence, the intronic sequence comprising two identical donor sites and one acceptor site, and d) a coding sequence of a heterologous protein, the coding sequence being operably linked to a promoter. 20. The expression vector of claim 19 wherein said fetuin coding sequence is either human, bovine, or a homolog or ortholog thereof. 21. An expression vector of claim 19 identified as pSV-AHSG. 22. An expression vector of claim 19 identified as pCMGGF2. 23. An isolated Glial Growth Factor 2 protein produced by the method of claim 1. 24. A host cell transformed by the expression vector of claim 21. 25. A host cell transformed by the expression vector of claim 22. 26. A host cell of claim 24 further transformed by the expression vector pCMGGF2. 27. An isolated Gilial Growth Factor 2 protein produced by a host cell of claim 25. 28. An isolated Gilial Growth Factor 2 protein produced by a host cell of claim 26.

Inventors: CHAN SHAM YUEN, CHENG SHU-LAN, TRAN VAN-MAI, CHAN, SHAM, YUEN, CHENG, SHU-LAN, TRAN, VAN-MAI
Applicants: BAYER AG, CHAN SHAM YUEN, CHENG SHU LAN, TRAN VAN MAI, BAYER CORPORATION, CHAN, SHAM, YUEN, CHENG, SHU-LAN, TRAN, VAN-MAI
Application year: 1999
Main classification: C12N15
IPC codes: C07K14, C12N5, C12N15, C12P21, C12R1